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Interferon receptor alpha/beta is associated with improved survival
after adjuvant therapy in resected pancreatic cancer
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Abstract
Aim. Interferons (IFNs) are known to have antiproliferative and immunoregulatory activities that are modulated through
specific cell surface ligands, known as IFN-a, -b, and -g receptors. The presence of these receptors and their impact on
response to adjuvant therapy in patients with pancreatic cancer has not been determined. Patients and methods. Slides were
prepared from 46 patients with pancreatic adenocarcinoma. Immunohistochemistry (IHC) was subsequently used to
determine the expression of IFN- a/b receptor-chain 2 (IFN-a/bR) and IFN-g receptor-chain 1 (IFN-gR). The correlation
between IFN receptor expression, tumor characteristics, and the overall patient response to adjuvant therapy were
determined analytically. Results. The IHC performed for pancreatic adenocarcinoma demonstrated a high IFN-a/bR
expression in 4% (2/46) of patients, moderate expression in 20% (9/46) of patients, and faint or no expression in 76%
(35/46) of patients. IHC confirmed a high expression of IFN-gR in 52% (24/46) of patients, moderate expression in 35%
(16/46) of patients, and faint or no expression in the remaining 13% (6/46) of patients. Thirty-two (69.7%) patients
received adjuvant therapy. Clinicopathological survey did not demonstrate any significant correlation between IFN-a/bR
and IFN-gR expression with regard to tumor size, vascular invasion, perineural invasion, lymph node metastases, or stage of
disease. Use of adjuvant therapy was associated with increased survival in patients with IFN-a/bR-positive tumors compared
with patients with IFN-a/bR-negative tumors (24 months versus 14.7 months in log rank test, p0.012). The expression of
IFN-gR, however, had no impact on patient survival (20 months vs 17 months; p0.656, log rank test). Conclusion. IFN-a/
bR is associated with improved survival for patients with resectable pancreatic cancer who received adjuvant therapy.
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Introduction
Pancreatic carcinoma accounted for 30 700 new cases
and 30 000 deaths in 2002 and represents the fourth
leading cause of cancer-related death in the United
States [1]. The diagnosis of pancreatic carcinoma
carries a dismal prognosis, with a 5-year survival
of 3% and median survivals of B6 months [2,3].
Operative intervention alone rarely achieves a curative
endpoint [2] and therefore adjuvant therapies are
required to facilitate survival and control disease. A
desired strategy to improve care is to individualize
cancer treatment by directing our patients towards
those modalities that are more likely to offer a benefit
according to their particular tumor or individual
attributes. A cancer biomarker can be defined as
a biological feature that provides diagnostic, prognos-
tic, predictive, or therapeutic information about a
particular disease or subject. Some fundamental
aspects are worth considering when searching for
a biomarker. The rapidly expanding knowledge of
the pathogenesis of pancreatic cancer at the mole-
cular level is providing new targets for disease
characterization, early diagnosis, and drug discovery
and development.
Recently, we were able to show that interferons
(IFNs) have antitumoral and apoptotic effects on
those pancreatic cancer cell lines that specifically
express the corresponding IFN receptors [4]. Also,
IFNs were found to augment the antitumoral effects
of 5-fluorouracil (5-FU) and gemcitabine only in
those cell lines that express the IFN receptor [4].
The apoptotic effects of IFNs are mediated through
the caspase cascade [4]. We have previously reported
that patients with pancreatic cancer who expressed
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IFN receptor alpha/beta (IFN-a/bR) had better sur-
vival compared with patients who did not express this
receptor [5]. Here, we correlate the expression of IFN
receptors with survival after adjuvant therapy.
Patients and methods
The study was performed at the authors’ institution
and included 46 patients with pancreatic ductal
carcinoma who had undergone a curative operative
resection from 1990 to 2002. In all patients, the
specimens were fixed with formalin, embedded in
paraffin, and cut into consecutive 4 mm thick sections.
Standard staining techniques with hematoxylin and
eosin (H&E) were performed. The slides that con-
tained pancreatic tissue with invasive neoplasm were
selected and reviewed. Also, slides that contained
normal sections of pancreas were analyzed for IFN
receptor and were confirmed to be tumor-free. A
senior pathologist reviewed the histopathology
blinded to the data collection. Patient data and
characteristics of the neoplasm were collected from
the tumor registry. None of the patients received IFN-
based treatment. Since blood serum was not available,
the measurement of serum IFN was not done.
Immunohistochemistry
Immunohistochemical staining was performed by the
immunoperoxidase technique. Paraffin sections of the
formalin-fixed tissues were dewaxed through five
changes of xylene, rinsed in graded ethanol solutions,
and finally rehydrated in three changes of phosphate-
buffered saline (PBS). Antigen retrieval to enable
IFN-a/bR staining was facilitated by microwave
treatment to unmask tissue antigens. Endogenous
peroxidase was blocked by incubating the sections in
0.3% hydrogen peroxidase in methanol for 30 min at
room temperature. After rinsing three times with PBS
for 5 min, nonspecific reactions were blocked by
incubating the sections with PBS containing 5%
normal rabbit or goat serum for 30 min at room
temperature. The sections were then incubated with
appropriate dilutions of the primary antibody at 48C
overnight.
To facilitate identification of the IFN-gR, a rabbit
polyclonal IgG antibody (R&D Systems Inc., Min-
neapolis, MN, USA) at a 1:200 dilution was used,
whereas for the IFN-a/bR, a goat polyclonal IgG
antibody (R&D Systems Inc.) at a 1:200 dilution was
used. The sections were rinsed three times with PBS
for 5 min and incubated for 30 min with appropriate
dilutions of the secondary antibody at room tempera-
ture. Each of the sections was then incubated for 30
min by the avidin biotin complex (ABC) method in
accordance with the manufacturer’s instructions
(Dako, Glostrup, Denmark). Additional rinsing with
PBS was then performed three times for 5 min and
the sections were incubated with diaminobenzidine
substrate for 3 min. The sections were rinsed finally
with distilled water and counterstained with Mayer’s
hematoxylin solution.
Evaluation of immunostaining
The slides were evaluated to determine objectively the
intensity of IHC staining using a standardized grading
system. The immunoreactivity of the cancer cells for
IFN-a/bR and IFN-gR was graded on a scale of 02
based on the number of cells stained and the intensity
of the reaction within individual cells. The grades
were defined as follows: 0025% of the cells (weak
staining); 12650% (weak to moderate staining);
251100% (moderate to strong staining). The
slides were stained twice and examined randomly by
independent, blinded investigators to facilitate accu-
racy and limit the inter-observer bias. Intra-observer
variation was B5% in each of the three investigator
grades.
Statistical analysis
The x2 test was used to evaluate the relationships
between the expression of IFN receptors and the
following clinicopathologic parameters: age, gender,
size of neoplasm, tumor grade, vascular invasion,
perineural invasion, depth of neoplasm, nodal status,
resection margin status, and stage of disease. Kaplan
Meier analysis was used to assess the relationship
between IFN receptor expression and overall survival
(median).
Results
The IHC performed for pancreatic adenocarcinoma
demonstrated high IFN-a/bR expression in 2/46 (4%)
of patients, moderate expression in 9/46 (20%)
(Figure 1), and faint or no expression in 35/46
(76%). IHC confirmed a high expression of IFN-gR
in 24/46 (52%) of patients (Figure 1), moderate
expression in 16/46 (35%), and faint or no expression
in the remaining 6/46 (13%) of patients (Table I). By
comparison, 27% and 45% of the corresponding
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Figure 1. Survival of patients based on their IFN-a/b receptor
expression and adjuvant therapy.
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noncancerous normal pancreatic tissue in the same
patients showed a high expression of IFN-a/bR and
IFN-gR, respectively.
There was no correlation between the expression
of IFN-a/bR or IFN-gR and the clinicopathologic
features. These features included: age, gender, tumor
size, vascular invasion, perineural invasion, tumor
depth, nodal status, and stage of disease (Table II).
Thirty-two patients (70%) received adjuvant therapy
which was mainly based on 5-FU.
Use of adjuvant therapy was associated with in-
creased survival in patients with IFN-a/bR-positive
tumors compared with patients with IFN-a/bR-
negative tumors (24 months vs 14.7 months in log
rank test, p0.012). As shown in Table III and
Figure 1, patients who expressed IFN-a/bR and
received adjuvant therapy had significantly better
survival compared with other groups. As shown in
Figure 2, the expression of IFN-gR had no impact on
patient survival (20 months vs 17 months; p0.656,
log rank test) regardless of whether they received
adjuvant therapy or not.
Figure 3 shows the expression of IFN-a/bR and
IFN-gR in pancreatic cancer.
Discussion
In 2005, nearly 34 000 Americans were diagnosed
with pancreatic cancer and 32 300 died of the disease
[1]. Only a minority of newly diagnosed pancreatic
cancer patients are considered eligible for resection.
Five-year survival rates in those who undergo an
attempted curative procedure are only 824% [2,3].
Adjuvant chemoradiation or chemotherapy is usually
recommended to eligible patients after the resection
procedure. Although not conclusive, recent data
results showed a trend toward benefit of adjuvant
therapy [2,3]. Opportunities for improvement in
Table I. Expression of IFN receptors in patients with pancreatic
cancer.
Variable
Negative
or faint
Moderately
positive
Strongly
positive
IFN-a/b
receptor 76.08% (35/46) 19.56% (9/46) 2.17% (2/46)
IFN-g
receptor 13.04% (6/46) 34.78% (16/46) 52.12% (24/46)
Table II. Relationship between expression of IFN-a/b receptor or IFN-g receptor and clinicopathologic factors.
IFN-a/b receptor IFN-g receptor
Positive Negative Strong Not strong
Parameters (n11) (n35) p* (n24) (n22) p
Age (mean) 68.8 65.7 NS 67.7 66.9 NS
Gender (M/F) 7/4 20/15 NS 14/10 12/10 NS
Tumor extent (pT$) NS NS
T0 1 0 1 0
T1 0 4 5 6
T2 4 11 8 6
T3 6 20 10 10
Nodal involvement (pN$) NS NS
N0 6 20 10 12
N1 5 15 14 10
Positive margin 2 6 NS 5 15 NS
Grading NS NS
Well 2 5 4 1
Moderate 4 11 9 11
Poor 5 19 11 10
Vascular invasion NS NS
Positive 7 22 13 12
Negative 4 13 11 10
Perineural invasion NS NS
Positive 6 20 11 11
Negative 5 15 13 11
Stage$ NS NS
0I 2 10 6 8
IIIII 9 25 18 14
Adjuvant therapy 7 25 NS 17 15 NS
NS, not statistically significant.
*p value was calculated by x2 test or Fisher’s exact test.
$Based on AJCC, 6th edn.
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outcome will likely come from improvements in early
detection strategies, better identification of precursor
lesions and high-risk groups, and from ongoing trials
designed to identify active agents (chemotherapeutic,
immunotherapeutic, and other) and implement their
use in appropriate patient groups. Gene and protein
expression profiling has advanced our understanding
of pancreatic ductal adenocarcinoma, identifying
genes that are highly expressed in pancreatic cancers,
providing more insight into the clinicopathologic
features of pancreatic cancer, and revealing novel
features related to the process of tissue invasion by
these tumors. The increasing knowledge of the path-
way activation profile in pancreatic cancer is yielding
new targets but also new markers to select patients
and to guide and predict therapy efficacy. The
discovery of genetic factors the presence of which
predisposes pancreatic cancer to successful targeting,
such as the association of BRCA2/Fanconi anemia
gene defects and sensitivity to mitomycin C, will
eventually lead to a more individualized treatment
approach.
Adjuvant IFN therapy may hold promise for
patients with pancreatic carcinoma. IFNs are known
to bind to receptors on the cell surface that facilitate
activation of Janus kinase/signal transduction pathway
that result in activation of other transcription path-
ways [69]. The systemic effects in patients with
pancreatic cancer have not been clearly elucidated. In
fact, numerous phase II trials have been conducted
that utilize IFN therapy in combination with other
agents, such as 5-FU and leucovorin, to treat patients
with metastatic or locally advanced pancreatic cancer
[1017]. However, the results from these early trials
were not encouraging. More recently, investigators of
a phase II trial that used IFN-a/cisplatin/5-FU-based
adjuvant chemoradiation after pancreaticoduodenec-
tomy have reported unsurpassed 2-year survival rates
for patients with resected pancreatic cancer [18,19].
Recently, a trial from the Virginia Mason Medical
Center showed encouraging survival data with a novel
IFN-based chemoradiation regimen [20,21]. In their
study, 43 patients underwent pancreaticoduodenect-
omy for pancreatic cancer. These patients then
received external beam radiation at a dose of 4500
5400 cGy (25 fractions 5 weeks) and three-drug
chemotherapy: continuous infusion 5-FU (200 mg/m2
daily on days 135), weekly intravenous bolus cispla-
tin (30 mg/m2 daily on days 1, 8, 15, 22, and 29),
and subcutaneous IFN-a (3106 U on days 135).
This regimen was followed up by continuous infusion
5-FU (200 mg/m2 daily on weeks 914 and 1722).
The treatment was generally initiated between 6 and
8 weeks after surgery. The mean follow-up time
was 31.9 months, and 67% of the patients were
alive at this time, although median survival had
not been reached at the time of publication. The
actuarial overall survival for the 1-, 2-, and 5-year
periods was 95% (95% confidence interval [CI] 91
98%), 64% (95% CI 5672%), and 55% (95% CI
4665%), respectively. These results were obtained
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Figure 2. Expression of IFN-g receptor did not predict response to
adjuvant therapy.
Figure 3. Immunohistochemistry demonstrating moderate expres-
sion of the IFN-a/b (A) and IFN-g receptors (B).
Table III. Patients’ survival based on the IFN-a/b receptor and
adjuvant therapy (AT).
Variable Mean 95% CI
IFN-a/bR/AT(n6) 24.4* 16.236.8
IFN-a/bR/AT (n5) 14.7 9.218.7
IFN-a/bR/AT (n26) 16.2 8.222.6
IFN-a/bR/AT (n9) 13.6 7.817.5
CI, confidence interval.
*pB0.01.
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despite a high incidence of lymph node involve-
ment and advanced tumor stage. One major drawback
to this regimen, however, was the associated toxicity.
In all, 42% of patients were hospitalized during
the treatment, mostly because of gastrointestinal
toxicity. From this limited patient series, however,
the actuarial 2- and 5-year overall survival rates
suggest a significant potential for improved long-
term survival. Because these results showed a remark-
able improvement compared with accepted regimens,
the American College of Surgeons carefully audited
the study data and reconfirmed their accuracy. The
American College of Surgeons Oncology group has
since supported a large multicenter, phase II study
(Z05031A2) to further evaluate IFN-a-based adju-
vant therapy for resectable pancreatic cancer [22].
We determined the presence of IFN receptors in
pancreatic cancer and the impact that each type had
on patient survival after adjuvant therapy. We found
that IFN-gR was expressed in 85% of patients with
pancreatic cancer. However, expression of this recep-
tor had no significant impact on patient survival
regardless of whether or not adjuvant treatment was
given. IFN-a/bR was expressed in only 25% of
patients in the pancreatic cancer tissue compared
with 27% in non-cancerous pancreatic parenchyma.
These patients had a more favorable survival, if they
received adjuavant therapy. In fact, the mean survival
for patients with IFN-a/bR-positive neoplasm who
received adjuvant therapy was 24.4 months. Further-
more, expression of the IFN-a/bR did not correlate
with lymphovascular or perineural invasion, lymph
node metastases, size, or stage of neoplasm. There-
fore, the data would suggest that IFN-a/bR can
predict response to adjuvant therapy after pancreatic
resection.
Adjuvant therapy may improve long-term survival
in patients with resected pancreatic cancer [2325],
but its routine use is not universal [23]. The European
Study Group for Pancreatic Cancer (ESPAC) recently
published their results for 73 patients with resected
pancreatic ductal adenocarcinoma who were treated
with chemoradiotherapy alone (20 Gy over a 2-week
period plus fluorouracil), 75 patients who received
chemotherapy alone (fluorouracil), 72 patients with
both chemoradiotherapy and chemotherapy, and 69
patients without treatment (observation only) [25].
The estimated 5-year survival rate was 10% among
patients assigned to receive chemoradiotherapy and
20% among patients who did not receive chemor-
adiotherapy (p0.05). The 5-year survival rate
was 21% among patients who received chemotherapy
and 8% among patients who did not receive chemo-
therapy (p0.009). Based on the results it seems that
adjuvant chemotherapy has a significant survival
benefit in patients with resected pancreatic cancer,
whereas adjuvant chemoradiotherapy has a deleter-
ious effect on survival.
Although the information provided by our research
is unique, the study itself has several shortcomings.
First, the number of patients in our series was small.
Second, it may have been helpful to know the serum
IFN levels, which may have explained why the
patients with IFN-a/bR expression have better survi-
val. It was not possible, however, to assay these levels
secondary to the retrospective collection of patient
data. Lastly, the results of our study should prompt
further validation, perhaps by other investigators with
larger series of patients.
In summary, our study showed that expression of
IFN-a/bR was associated with improved survival
for patients with resectable pancreatic cancer who
received adjuvant therapy. Interestingly, we have
determined recently that IFNs enable apoptosis in
human pancreatic cancer cell lines that express the
IFN receptor [4]. We believe that these data may
influence future targeted therapies for those patients
with receptor-positive neoplasms. Further clinical
trials are necessary to determine the utility of such
treatments.
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